Home or
 

Keywords :   


Tag: or

Nioh lets the player decide what matters most: frame rate or fidelity

2017-02-07 16:30:01| Extremetech

Nioh undoubtedly takes inspiration from Dark Souls, but it sets itself apart thanks largely to Team Ninja's knack for clever combat systems. Even better, the developers let players decide whether to prioritize the responsiveness of 60fps or the additional visual fidelity granted by halving the frame rate. The post Nioh lets the player decide what matters most: frame rate or fidelity appeared first on ExtremeTech.

Tags: or rate player frame

 

Dodd-Franks Tentacles Go Deep. They Wont Be Cut Fast or Easily

2017-02-06 16:50:00| National Real Estate Investor

It has taken seven years to put in place the regulatory strictures imposed on Wall Street after the financial crisis. They wont be removed fast or easily. read more

Tags: or fast easily cut

 
 

European Medicines Agencys CHMP Recommends Mercks KEYTRUDA (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor...

2016-12-16 13:26:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Opinion Based on Findings from KEYNOTE-024 Trial, Which Showed Superior Overall Survival and Progression Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy to Receive a CHMP Positive Opinion for Previously Untreated Patients with Metastatic NSCLC KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tu Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

Tags: or with high positive

 

Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection

2016-11-13 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Phase 2 Data Presentations at The Liver Meeting Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1), the companys investigational all-oral, triple-combination regimen for the treatment of chronic hepatitis C (HCV) infection (informally referred to as MK3). Language: English Contact: Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: or high people showing

 

UNICEF: 300M children worldwide breathing air exceeding WHO pollution guidelines by 6x or more

2016-10-31 18:55:26| Green Car Congress

Tags: or more air children

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] next »